ArticleMolecular and cellular biology2001
Reduction of target gene expression by a modified U1 snRNA.
Article in Molecular and cellular biology, 2001. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 44 citations in OpenAlex.
- Emerging Roles of RNA 3'-end Cleavage and Polyadenylation in Pathogenesis, Diagnosis and Therapy of Human Disorders.Biomolecules · 2020Review
- High-throughput identification of synthetic riboswitches by barcode-free amplicon-sequencing in human cells.Nature communications · 2020Article
- A multicolor riboswitch-based platform for imaging of RNA in live mammalian cells.Nature chemical biology · 2018Article
- The reciprocal regulation between splicing and 3'-end processing.Wiley interdisciplinary reviews. RNA · 2016Review
- Conditional U1 Gene Silencing in Toxoplasma gondii.PloS one · 2015Article
- Quality control of assembly-defective U1 snRNAs by decapping and 5'-to-3' exonucleolytic digestion.Proceedings of the National Academy of Sciences of the United States of America · 2014Article
- Alternative polyadenylation of tumor suppressor genes in small intestinal neuroendocrine tumors.Frontiers in endocrinology · 2014Article
- U1 adaptors for the therapeutic knockdown of the oncogene pim-1 kinase in glioblastoma.Nucleic acid therapeutics · 2013Article
- Alterations in polyadenylation and its implications for endocrine disease.Frontiers in endocrinology · 2013Article
- U1 snRNP-Dependent Suppression of Polyadenylation: Physiological Role and Therapeutic Opportunities in Cancer.International journal of cell biology · 2013Review
- An exon-specific U1 small nuclear RNA (snRNA) strategy to correct splicing defects.Human molecular genetics · 2012Article
- Increased in vivo inhibition of gene expression by combining RNA interference and U1 inhibition.Nucleic acids research · 2012Article
- Article
- Excessive RNA splicing and inhibition of HIV-1 replication induced by modified U1 small nuclear RNAs.Journal of virology · 2010Article
- Combination of RNA interference and U1 inhibition leads to increased inhibition of gene expression.Nucleic acids research · 2010Article
- Ectopic 5' splice sites inhibit gene expression by engaging RNA surveillance and silencing pathways in plants.Plant physiology · 2009Article
- Gene silencing by synthetic U1 adaptors.Nature biotechnology · 2009Article
- Requirements for gene silencing mediated by U1 snRNA binding to a target sequence.Nucleic acids research · 2008Article
- Reduction of human chorionic gonadotropin beta subunit expression by modified U1 snRNA caused apoptosis in cervical cancer cells.Molecular cancer · 2008Article
- A bipartite U1 site represses U1A expression by synergizing with PIE to inhibit nuclear polyadenylation.RNA (New York, N.Y.) · 2007Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
Abstract
Although the primary function of U1 snRNA is to define the 5' donor site of an intron, it can also block the accumulation of a specific RNA transcript when it binds to a donor sequence within its terminal exon. This work was initiated to investigate if this property of U1 snRNA could be exploited as an effective method for inactivating any target gene. The initial 10-bp segment of U1 snRNA, which is complementary to the 5' donor sequence, was modified to recognize various target mRNAs (chloramphenicol acetyltransferase [CAT], beta-galactosidase, or green fluorescent protein [GFP]). Transient cotransfection of reporter genes and appropriate U1 antitarget vectors resulted in >90% reduction of transgene expression. Numerous sites within the CAT transcript were suitable for targeting. The inhibitory effect of the U1 antitarget vector is directly related to the hybrid formed between the U1 vector and target transcripts and is dependent on an intact 70,000-molecular-weight binding domain within the U1 gene. The effect is long lasting when the target (CAT or GFP) and U1 antitarget construct are inserted into fibroblasts by stable transfection. Clonal cell lines derived from stable transfection with a pOB4GFP target construct and subsequently stably transfected with the U1 anti-GFP construct were selected. The degree to which GFP fluorescence was inhibited by U1 anti-GFP in the various clonal cell lines was assessed by fluorescence-activated cell sorter analysis. RNA analysis demonstrated reduction of the GFP mRNA in the nuclear and cytoplasmic compartment and proper 3' cleavage of the GFP residual transcript. An RNase protection strategy demonstrated that the transfected U1 antitarget RNA level varied between 1 to 8% of the endogenous U1 snRNA level. U1 antitarget vectors were demonstrated to have potential as effective inhibitors of gene expression in intact cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.